Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese
patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang
Caplsule plus triple therpy) for eradicating Helicobacter pylori in IgA nephropathy.